Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME)

Victory Capital Management Inc. increased its holdings in shares of Zymeworks Inc. (NYSE:ZYME) by 23.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,300 shares of the company’s stock after buying an additional 11,100 shares during the period. Victory Capital Management Inc. owned about 0.08% of Zymeworks worth $496,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in ZYME. Rubric Capital Management LP boosted its position in Zymeworks by 31.1% during the 4th quarter. Rubric Capital Management LP now owns 3,475,384 shares of the company’s stock worth $36,109,000 after buying an additional 823,990 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Zymeworks during the 1st quarter worth approximately $6,301,000. Jacobs Levy Equity Management Inc. raised its holdings in Zymeworks by 94.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 716,482 shares of the company’s stock worth $7,537,000 after purchasing an additional 348,441 shares during the last quarter. Altitude Crest Partners Inc. bought a new position in Zymeworks during the 1st quarter worth approximately $1,532,000. Finally, O Shaughnessy Asset Management LLC raised its holdings in Zymeworks by 51.5% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 255,497 shares of the company’s stock worth $2,688,000 after purchasing an additional 86,797 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on ZYME shares. HC Wainwright restated a “neutral” rating and set a $10.00 price target on shares of Zymeworks in a report on Wednesday, September 18th. Stifel Nicolaus raised their price target on shares of Zymeworks from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, August 2nd.

Zymeworks Stock Up 0.3 %

NYSE:ZYME opened at $13.09 on Monday. The company has a fifty day moving average of $11.03 and a 200-day moving average of $9.88. The firm has a market capitalization of $925.53 million, a P/E ratio of -7.31 and a beta of 1.19. Zymeworks Inc. has a twelve month low of $6.01 and a twelve month high of $13.23.

Zymeworks (NYSE:ZYME) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The company had revenue of $19.24 million during the quarter, compared to analyst estimates of $23.16 million. Zymeworks had a negative net margin of 179.42% and a negative return on equity of 21.97%. During the same quarter in the previous year, the business posted ($0.76) EPS. On average, analysts anticipate that Zymeworks Inc. will post -0.85 EPS for the current fiscal year.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.